Expert Interview
A Second View: Taking a look at the ongoing NTLA's study of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy and BBIO's phase 3 attribute-cm study of acoramidis in patients with transthyretin (ATTR) amyloidosis
Ticker(s): NTLA, BBIOInstitution: Hospital Clinico San Carlos
- Cardiology Consultant in the field of Cardiac Imaging, specifically oriented to Cardiac CT, Cardiac MR and Echocardiography guidance of structural heart disease procedures.
- Treats 20 patients with attr-cm
- Author of more than 50 articles in international journals and several chapters in cardiology books.
- Has presented over 100 communications in national and international congresses
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
